Covagen gets up to $63M in VC round for multitargeted antibodies FierceBiotech Researchers at Swiss biotech startup Covagen are in the business of building multitargeted antibodies, new bi- and trispecific therapies which are created by fusing short proteins onto the arms and tail of the Y-shaped body of the original structure ... Covagen Secures CHF 42 Million in Series B Financing |
